Browse News
Filter News
Found 210 articles
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
3/25/2024
Nkarta, Inc. announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock.
-
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
3/21/2024
Pyxis Oncology, Inc. today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update.
-
Pyxis Oncology Announces $50 Million Private Placement
2/27/2024
Pyxis Oncology, Inc. today announced that it has agreed to sell 8,849,371 shares of its common stock at a price of $4.78 per share.
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
11/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.
-
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
7/31/2023
Emergent BioSolutions Inc. announced that it was awarded a 10-year contract by the BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga™, a licensed treatment for Ebola virus disease.
-
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
2/24/2023
Merck and Ridgeback Biotherapeutics today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the refusal of the marketing authorization for LAGEVRIO™ (molnupiravir) for the treatment of certain adults who have been diagnosed with COVID-19 in the European Union (EU).
-
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
2/21/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19.
-
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
2/15/2023
NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending December 31, 2022 with the Securities and Exchange Commission on Tuesday, February 14, 2023.
-
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
2/2/2023
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.
-
Merck Announces Third-Quarter 2022 Financial Results
10/27/2022
Merck, known as MSD outside the United States and Canada, announced financial results for the third quarter of 2022.
-
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
10/6/2022
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today issued the following announcement regarding data from two real-world evidence studies evaluating LAGEVRIO™ (molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
8/1/2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2022.
-
Merck Announces Second-Quarter 2022 Financial Results
7/28/2022
Merck, known as MSD outside the United States and Canada, announced financial results for the second quarter of 2022. This press release features multimedia.
-
Oral Solid Dosage Pharmaceutical Market Landscape Dominated By Immediate Drug Release Mechanism: Fact.MR Study
7/26/2022
Fact.MR – A Market Research and Competitive Intelligence Provider: The global oral solid dosage pharmaceutical market is set to experience robust growth at 6.4% CAGR and cross a market valuation of US$ 1 trillion by the end of 2032.
-
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola
7/7/2022
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intended to create a collaboration to expand the availability of Ebanga™ (Ansuvimab-zykl).
-
Even though the COVID-19 pandemic appears to be under control, it's clear that it's not over, with the rise of more subvariants. Read on for more details.
-
Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.
-
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
6/7/2022
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO ™ (molnupiravir) From Phase 3 MOVe-OUT Study.
-
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
-
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.